贝伐珠单抗注射液联合紫杉醇注射液和顺铂注射液治疗卵巢肿瘤的临床研究

目的探讨贝伐珠单抗注射液联合紫杉醇注射液和顺铂注射液治疗卵巢肿瘤患者的疗效。方法选择我院2016年8月至2018年9月收治的卵巢肿瘤患者96例,随机分为两组各48例。对照组采用紫杉醇注射液和顺铂注射液治疗,观察组在对照组基础上采用贝伐珠单抗注射液治疗,两组患者均治疗21 d为1个周期,共治疗3个周期。比较两组的治疗效果,以及治疗前后的糖类抗原125 (CA125)、组织多肽抗原(TPA)、甲胎蛋白(AFP)、癌胚抗原(CEA)水平。结果观察组的治疗有效率为85.42%,显著高于对照组的60.42%(P<0.05)。治疗后,两组患者的CA125、TPA、AFP、CEA水平均显著降低(P<0.05),且观察组的CA125、TPA、AFP、CEA水平均显著低于对照组(P<0.05)。结论贝伐珠单抗注射液联合紫杉醇和顺铂注射液治疗卵巢肿瘤患者具有显著的临床疗效,可降低肿瘤标志物水平,具有较高的临床应用价值。

Clinical Study of Bevacizumab Injection Combined with Paclitaxel Injection and Cisplatin Injection in the Treatment of Ovarian Cancer

Objective To explore the efficacy of bevacizumab injection combined with paclitaxel injection and cisplatin injection in the treatment of patients with ovarian cancer. Methods 96 patients with ovarian cancer admitted to our hospital from August 2016 to September 2018 were selected and randomly divided into two groups, with 48 cases in each group. The control group was treated with paclitaxel injection and cisplatin injection, and the observation group was treated with bevacizumab injection on the basis of the control group. Patients in both groups were treated for 3 cycles, with 21 days as 1 cycle. The curative effects, and the levels of carbohydrate antigen 125(CA125), tissue peptide antigen(TPA), alpha-fetoprotein(AFP), and carcinoembryonic antigen(CEA) before and after treatment were compared between the two groups.Results The effective rate of treatment in the observation group was 85.42%, significantly higher than60.42% in the control group(P<0.05). After treatment, the levels of CA125, TPA, AFP, and CEA in both groups decreased significantly(P<0.05), and the levels of CA125, TPA, AFP, and CEA in the observation group were significantly lower than those in the control group(P<0.05). Conclusions Bevacizumab injection combined with paclitaxel injection and cisplatin injection in the treatment of patients with ovarian cancer has significant clinical efficacy, which can reduce the levels of tumor markers, and has high clinical application value.